Program
sacituzumab govitecan
Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.
Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.
Drug pageSacituzumab govitecan: every studyAll 102 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 2317 open or running | phase 4since Mar 19, 2020 | Jun 26, 2012 | Dec 2026phase 1 · NCT04617522 |
| Merckits history only | 11 open or running | phase 3since Nov 2, 2022 | Nov 2, 2022 | Jan 12, 2027phase 3 · NCT05609968 |
Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 8 earlier studies, Jun 26, 2012 to Jun 5, 2020.
- Jun 9, 2015Named sacituzumab govitecanINNProposed as its International Nonproprietary Name in WHO's List 113
- Aug 19, 2020Phase 3 study in Locally Advanced or Metastatic Unresectable Urothelial CancerNCT04527991 · 711 enrolled · United States, Australia, Austria and more
- Nov 2, 2020Phase 1 study in Neoplasm MetastasisNCT04617522 · 30 planned · United States, France, Italy and more
- Nov 17, 2020Phase 3 study in Breast NeoplasmsNCT04639986 · 331 enrolled · China, South Korea, Taiwan
- Oct 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05089734 · 603 enrolled · United States, Australia, Austria and more
- Oct 19, 2021Phase 2 study in Triple Negative Breast NeoplasmsNCT05101096 · 135 enrolled · Japan
- Nov 3, 2021Phase 2 study in Solid TumorNCT05119907 · 53 enrolled · China
- Dec 23, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05186974 · 193 enrolled · United States, Australia, Canada and more
- May 16, 20222 phase 3 studies in Triple Negative Breast NeoplasmsNCT05382299, NCT05382286
- Nov 21, 2022Phase 2 study in Lung NeoplasmsNCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
- Nov 21, 2022Phase 3 study in Triple Negative Breast NeoplasmsNCT05633654 · 1,514 planned · United States, Australia, Belgium and more
- Apr 21, 2023Phase 3 study in Breast NeoplasmsNCT05840211 · 654 enrolled · United States, Argentina, Australia and more
- Jun 27, 2024Phase 3 study in Endometrial NeoplasmsNCT06486441 · 640 enrolled · United States, Australia, Brazil and more
- Jan 24, 2025Phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Apr 8, 2025Phase 2 study in Triple Negative Breast NeoplasmsNCT06926920 · 100 planned · United States, Australia, South Korea
Ahead
- Dec 2026Primary completion: phase 3 study in Breast NeoplasmsNCT04639986
- Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT04617522
- Feb 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT05382286
- Mar 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05186974
TargetBeta
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 23 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06926920Triple Negative Breast Neoplasms · United States, Australia, South Korea | 2 | Recruiting | Jun 2028 | 100 |
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Oct 2029 | 695 |
| NCT06486441Endometrial Neoplasms · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jun 2029 | 640 |
| NCT05840211Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 2028 | 654 |
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Sep 2029 | 192 |
| NCT05633654Triple Negative Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Jun 2027 | 1,514 |
| NCT05382299Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2028 | 623 |
| NCT05382286Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2027 | 443 |
| NCT05186974Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Mar 2027 | 193 |
| NCT05119907Solid Tumor · China | 2 | Active, not recruiting | Oct 2026 | 53 |
| NCT05101096Triple Negative Breast Neoplasms · Japan | 2 | Active, not recruiting | May 2027 | 135 |
| NCT05089734Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 29, 2023 | 603 |
| NCT04639986Breast Neoplasms · China, South Korea, Taiwan | 3 | Active, not recruiting | Dec 2026 | 331 |
| NCT04617522Neoplasm Metastasis · United States, France, Italy and more | 1 | Recruiting | Dec 2026 | 30 |
| NCT04527991Locally Advanced or Metastatic Unresectable Urothelial Cancer · United States, Australia, Austria and more | 3 | Completed | Jul 4, 2025 | 711 |
| NCT04454437Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Aug 6, 2021 | 80 |
| NCT04319198Metastatic Solid Tumors · United States, Belgium, France | 4 | Completed | Oct 18, 2024 | 25 |
| NCT03964727Neoplasm Metastasis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jan 15, 2025 | 227 |
| NCT03901339Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Oct 20, 2023 | 543 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Apr 2030 | 502 |
| NCT02574455Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Mar 30, 2020 | 529 |
| NCT02161679Triple Negative Breast Neoplasms | 2 | Withdrawn | Aug 2016 | 0 |
| NCT01631552Esophageal Neoplasms · United States | 2 | Completed | Mar 1, 2019 | 515 |
How it is read
Names in the registry
- “Sacituzumab Govitecan-hziy”, 12 entries
- “Sacituzumab Govitecan”, 4 entries
- “Sacituzumab Govitecan-hziy (SG)”, 4 entries
- “Sacituzumab govitecan-hziy (SG)”, 2 entries
- “Sacituzumab Govitecan (SG)”, 2 entries
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 7 studies
- Breast Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Carcinoma, Transitional Cell, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.